Houston is the first city in Texas to offer the Artificial Pancreas Treatment (APT). For the first time, the complications of diabetes, such as nephropathy and neuropathy, can be halted and even reversed, hypertension normalized, retinopathy halted and reversed, black toes saved, open wounds healed in weeks, and the entire milieu of diabetes complications, which are caused by improper metabolism, are effectively treated by restoring proper carbohydrate metabolism. With over 200,000 treatments there have been no reported adverse reactions.
Don’t confuse this with other pumps claiming to be an “artificial pancreas”. This is not the Medtronic “artificial pancreas,” widely publicized today. That device delivers subcutaneous insulin infusion (CSII) with an alarm and does not effectuate body-wide changes in carbohydrate metabolism.
What is the Trina Health Artificial Pancreas Treatment (APT)?
The Trina Health APT is intermittent pulsatile intravenous insulin therapy that should be used in combination with standard hypoglycemic treatments for the treatment of type I and type II diabetes mellitus.
Whereas the goal of conventional diabetic regimens is to reduce hyperglycemia and re-establish euglycemia, the function of the Trina Health APT is to correct abnormal carbohydrate metabolism, the underlying etiology of diabetes mellitus. This is accomplished by recapitulating the endogenous pulsatile secretion of insulin from the pancreas with first-pass metabolism by the liver, thus re-approximating its systemic metabolic effects of blood glucose regulation.
Novel Mechanism of Action
The Trina Health APT utilizes a patented, FDA-cleared Bionica Microdose infusion pump that re-approximates the periodicity and amplitude of pulsatile insulin secretion from the pancreas, thus recapitulating normal carbohydrate metabolism (Krebs cycle). This directly lowers lipid metabolism causing the tissues to have more cellular energy (ATP), and by reducing free fatty acids and reactive oxidative species (ROS), calms inflammatory cytokines while reducing overall oxygen requirements of the cells and helping to normalize blood flow by eliminating excessive free fatty acids. By promoting nitric oxide (which is cytotoxic) and with the additional ATP from carbohydrates, cellular (and thus organ) healing occurs body-wide.
Summary of Pathophysiologic Key Points
- Endogenous insulin is secreted in a pulsatile manner.
- Effects of pulsatile insulin:
- Loss of pulsatile insulin secretion leads to intrahepatic molecular changes and altered gene expression via delayed or impaired phosphorylation of intracellular insulin signaling proteins IRS-1, IRS-2, Akt, and Foxo1, consistent with development of hepatic insulin resistance.
- Increases hypoglycemic effect.
- Enhances peripheral glucose uptake.
- Maintains peripheral insulin receptor sensitivity.
- Up-regulates metabolic enzymes of glycolysis and the Krebs cycle, including glucokinase, phosphofructokinase, pyruvate kinase, pyruvate dehydrogenase, and acetyl-CoA carboxylase.
- Autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans leads to loss of pulsatile insulin secretion in patients with type I diabetes mellitus.
- Varying degrees of insulin resistance and relative insulin deficiency impair pulsatility of insulin release in patients with type II diabetes mellitus.
- Clinical Trial Results
- Intermittent pulsatile intravenous insulin therapy significantly lowers hemoglobin A1c (%) when used as adjunctive therapy with standard hypoglycemic regimens.
- Intermittent pulsatile intravenous insulin therapy may attenuate progression of diabetic nephropathy.
- Proven Experience
- APT has been studied for more than 25 years.
- Numerous clinical studies have been performed.
- FDA-cleared IV infusion pump by Bionica (1989)
- 6 patents
- Near 200,000 treatments to date
This therapy is now available at TRINA HEALTH WEST HOUSTON. Additional information is available at TrinaHealthHouston.com and Diabetes. Net, the Diabetes Network of Physicians and Scientists. Clinics are opening in China, India, Latin America, Europe, the Middle East and the USA.